Thus even though our data did not indicate serum CASC9 as a promising diagnostic biomarker, it appears to be a good candidate prognostic biomarker to be further exploited in prospective studies in patient with HCC. This evidence concerns the gene CASC9 and hepatocellular carcinoma.